CGF166
Total Payments
$654,423
Transactions
16
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $5,260 | 1 | 0 |
| 2019 | $204,175 | 4 | 0 |
| 2018 | $315,113 | 6 | 2 |
| 2017 | $129,874 | 5 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $654,262 | 11 | 100.0% |
| Food and Beverage | $160.44 | 5 | 0.0% |
Payments by Type
Research
$654,262
11 transactions
General
$160.44
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A THREE PART MULTICENTER OPEN LABEL SINGLE DOSE STUDY TO ASSESS THE SAFETY TOLERABILITY AND EFFICACY OF INTRA LABYRINTHINE IL CGF166 IN PATIENTS WITH SEVERE TO PROFOUND HEARING LOSS | Novartis Pharmaceuticals Corporation | $618,060 | 0 |
| LONG TERM SAFETY AND EFFICACY FOLLOW UP STUDY OF CGF166 TREATED PATIENTS | Novartis Pharmaceuticals Corporation | $36,202 | 0 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $654,423
Product Information
- Type Drug
- Total Payments $654,423
- Total Doctors 3
- Transactions 16
About CGF166
CGF166 is a drug associated with $654,423 in payments to 3 healthcare providers, recorded across 16 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $5,260 was paid across 1 transactions to 0 doctors.
The most common payment nature for CGF166 is "Unspecified" ($654,262, 100.0% of total).
CGF166 is associated with 2 research studies, including "A THREE PART MULTICENTER OPEN LABEL SINGLE DOSE STUDY TO ASSESS THE SAFETY TOLERABILITY AND EFFICACY OF INTRA LABYRINTHINE IL CGF166 IN PATIENTS WITH SEVERE TO PROFOUND HEARING LOSS" ($618,060).